2 weeks Ago By ABMN Staff
Biomea Fusion, Inc. ( NASDAQ:BMEA – Get Free Report ) saw some unusual options trading activity on Friday. Stock traders bought 9,805 call options on the company.
This is an increase of approximately 1,010% compared to the typical daily volume of 883 call options. Wall Street Analyst Weigh In Several brokerages recently commented on BMEA. Rodman & Renshaw upgraded shares of Biomea Fusion from a “neutral” rating to a “buy” rating and set a $18.
00 target price on the stock in a report on Thursday. Piper Sandler cut their price objective on Biomea Fusion from $45.00 to $10.
00 and set an “overweight” rating for the company in a research report on Friday, June 7th. Citigroup decreased their target price on Biomea Fusion from $45.00 to $22.
00 and set a “buy” rating for the company in a research note on Tuesday, August 27th. Truist Financial raised Biomea Fusion from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Friday.
Finally, Capital One Financial began coverage on Biomea Fusion in a research report on Thursday, August 29th. They issued an “overweight” rating and a $25.00 price objective for the company.
Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.
40. Read Our Latest Stock Analysis on BMEA Biomea Fusion Trading Up 3.4 % Biomea Fusion ( NASDAQ:BMEA – Get Free Report ) last issued its earnings results on Wednesday, July 31st.
The company reported ($1.03) EPS for the quarter, hitting the consensus estimate of ($1.03).
Sell-side analysts predict that Biomea Fusion will post -4.09 earnings per share for the current fiscal year. Hedge Funds Weigh In On Biomea Fusion A number of hedge funds and other institutional investors have recently made changes to their positions in BMEA.
Cubist Systematic Strategies LLC acquired a new position in shares of Biomea Fusion in the 2nd quarter worth approximately $109,000. Point72 Asia Singapore Pte. Ltd.
bought a new stake in Biomea Fusion in the second quarter valued at $36,000. Scientech Research LLC bought a new stake in Biomea Fusion in the second quarter valued at $46,000. Squarepoint Ops LLC acquired a new position in Biomea Fusion during the second quarter worth $237,000.
Finally, DRW Securities LLC bought a new position in shares of Biomea Fusion during the second quarter valued at $55,000. 96.72% of the stock is owned by institutional investors.
Biomea Fusion Company Profile ( Get Free Report ) Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Read More Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.
com's FREE daily email newsletter ..
